Lumen Bioscience has made clinical development progress on its lead candidate, LMN-201, an orally delivered biologic cocktail to treat and prevent a form of colitis called C. difficile infection (CDI). Lumen achieved FDA clearance for a planned Phase II study and successfully completed a Phase I first-in-human study, which validated drug delivery of enteric capsules into the gut. LMN-201 combines four therapeutic proteins that work synergistically to neutralize both the C. difficile bacterium and the toxin that causes its virulence . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge